ClinicalTrials.gg
CompletedNCT01517321Updated Jul 9, 2013

MK-0431/ONO-5435 Phase III Clinical Trial-Rapid-acting Insulin Secretagogue Add-on Study in Patients With Type 2 Diabetes

A Phase 3 interventional study of MK-0431/ONO-5435 and Placebo, MK-0431/ONO-5435 in Type 2 Diabetes, sponsored by Ono Pharmaceutical Co. Ltd. Completed at 6 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-07-09.

Sponsored by Ono Pharmaceutical Co. Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Phase 3
74 of 198
none open now
Registered
108th of 198
by date
Lead sponsor
5 of 198
Ono Pharmaceutical Co. Ltd

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is one of 74 in phase 3, and was the 108th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This Phase III clinical trial will examine the safety, tolerability, and efficacy of the addition of MK-0431/ONO-5435 to Japanese patients with Type 2 Diabetes mellitus who have inadequate glycemic control on diet/exercise therapy and rapid-acting insulin secretagogue monotherapy.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on diet/exercise therapy and rapid-acting insulin secretagogue monotherapy

Exclusion criteria

Exclusion Criteria:

  • Patients with Type 1 Diabetes Mellitus
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)

Study arms

  • Experimental
    E

    Drug: MK-0431/ONO-5435

  • Placebo comparator
    P

    Drug: Placebo, MK-0431/ONO-5435

Interventions

  • DrugMK-0431/ONO-5435

    Drug page: Sitagliptin

    Double-blind period (12 wk); 50 mg QD. The double-blind period will be followed by a 40 week open label extension period where MK-0431/ONO-5435 could be titrated from 50 mg to 100 mg QD.

  • DrugPlacebo, MK-0431/ONO-5435

    Double-blind period (12 wks); placebo QD. The double-blind period will be followed by a 40 wk open label extension period where MK-0431/ONO-5435 could be titrated from 50 mg to 100 mg QD.

06

What researchers measure

Primary outcomes

  1. Incidences of adverse experiences and change in vital sign, safety lab etc. as parameters of safety and tolerability

    Time frame: 12 weeks and 52 weeks

Secondary outcomes

  1. HbA1c

    Time frame: 12 weeks

  2. 2-hour postmeal glucose

    Time frame: 12 weeks

  3. Fasting plasma glucose

    Time frame: 12 weeks

07

Study locations

6 sites
  • Chubu Region Clinical Site
    Chubu, Japan
  • Chugoku Region Clinical Site
    Chugoku, Japan
  • Kanto Region Clinical Site
    Kanto, Japan
  • Kinki Region Clinical Site
    Kinki, Japan
  • Kyusyu Region Clinical Site
    Kyusyu, Japan
  • Tohoku Region Clinical Site
    Tohoku, Japan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 9, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01517321
Collaborators
MSD K.K.
Responsible party
Sponsor
First posted
Jan 25, 2012
Last update
Jul 9, 2013

Study contacts

Akiteru Seki
study chair · First Division Clinical Development Planning 1
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion